GTHX G1 Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GTHX

Price (delayed)

$4.49

Market cap

$234.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.59

Enterprise value

$261.7M

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the ...

Highlights
The company's EPS has surged by 79% YoY and by 37% QoQ
The company's net income has surged by 76% YoY and by 36% QoQ
The company's quick ratio fell by 40% YoY and by 26% QoQ
GTHX's equity is down by 38% year-on-year and by 22% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.g1therapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of GTHX
Market
Shares outstanding
52.28M
Market cap
$234.74M
Enterprise value
$261.7M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.45
Price to sales (P/S)
2.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.11
Earnings
Revenue
$84.04M
EBIT
-$18.55M
EBITDA
-$18.05M
Free cash flow
-$18.18M
Per share
EPS
-$0.59
Free cash flow per share
-$0.35
Book value per share
$0.53
Revenue per share
$1.61
TBVPS
$1.96
Balance sheet
Total assets
$102.03M
Total liabilities
$74.29M
Debt
$47.09M
Equity
$27.74M
Working capital
$63.24M
Liquidity
Debt to equity
1.7
Current ratio
2.94
Quick ratio
2.36
Net debt/EBITDA
-1.49
Margins
EBITDA margin
-21.5%
Gross margin
91.9%
Net margin
-36.4%
Operating margin
-27.2%
Efficiency
Return on assets
-24.3%
Return on equity
-74.8%
Return on invested capital
-17.3%
Return on capital employed
-26.7%
Return on sales
-22.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GTHX stock price

How has the G1 Therapeutics stock price performed over time
Intraday
1.13%
1 week
12.53%
1 month
-4.87%
1 year
48.68%
YTD
47.21%
QTD
3.94%

Financial performance

How have G1 Therapeutics's revenue and profit performed over time
Revenue
$84.04M
Gross profit
$77.23M
Operating income
-$22.83M
Net income
-$30.59M
Gross margin
91.9%
Net margin
-36.4%
GTHX's operating margin has surged by 86% year-on-year and by 43% since the previous quarter
GTHX's net margin has soared by 83% YoY and by 37% QoQ
The company's operating income has surged by 80% YoY and by 42% QoQ
The company's net income has surged by 76% YoY and by 36% QoQ

Growth

What is G1 Therapeutics's growth rate over time

Valuation

What is G1 Therapeutics stock price valuation
P/E
N/A
P/B
8.45
P/S
2.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.11
The company's EPS has surged by 79% YoY and by 37% QoQ
The P/B is 117% above the 5-year quarterly average of 3.9 and 106% above the last 4 quarters average of 4.1
GTHX's equity is down by 38% year-on-year and by 22% since the previous quarter
The price to sales (P/S) is 92% lower than the 5-year quarterly average of 35.2 but 64% higher than the last 4 quarters average of 1.7
GTHX's revenue is up by 47% YoY

Efficiency

How efficient is G1 Therapeutics business performance
The company's return on sales has surged by 89% YoY and by 48% QoQ
The ROIC has soared by 81% year-on-year and by 41% since the previous quarter
The ROA has soared by 66% YoY and by 29% from the previous quarter
GTHX's ROE has soared by 66% YoY and by 29% from the previous quarter

Dividends

What is GTHX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GTHX.

Financial health

How did G1 Therapeutics financials performed over time
The company's total assets is 37% higher than its total liabilities
The company's quick ratio fell by 40% YoY and by 26% QoQ
The company's total assets fell by 37% YoY and by 16% QoQ
GTHX's debt is 70% higher than its equity
GTHX's debt is down by 43% YoY and by 16% QoQ
GTHX's equity is down by 38% year-on-year and by 22% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.